惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

B
Blog
量子位
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
Last Week in AI
Last Week in AI
酷 壳 – CoolShell
酷 壳 – CoolShell
人人都是产品经理
人人都是产品经理
Jina AI
Jina AI
雷峰网
雷峰网
博客园_首页
WordPress大学
WordPress大学
博客园 - 司徒正美
爱范儿
爱范儿
博客园 - 聂微东
IT之家
IT之家
美团技术团队
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
博客园 - 三生石上(FineUI控件)
有赞技术团队
有赞技术团队
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
T
Tailwind CSS Blog
博客园 - Franky
V
V2EX
GbyAI
GbyAI
阮一峰的网络日志
阮一峰的网络日志

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
UroGen Pharma Ltd. (URGN) Discusses Real-World Experience...
2026-05-18 · via All Articles on Seeking Alpha

UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer May 17, 2026 8:30 AM EDT

Company Participants

Elizabeth Barrett - President, CEO & Director
Mark Schoenberg - Chief Medical Officer
Vincent Perrone - Senior Director of Investor Relations

Conference Call Participants

Aaron Berger
Karim Chamie
Jennifer Linehan
Nicholas Lorusso - TD Cowen, Research Division
Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division
Mohamad Amin Makarem - Jefferies LLC, Research Division
Kelsey Goodwin - Piper Sandler & Co., Research Division
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division
Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division

Presentation

Elizabeth Barrett
President, CEO & Director

Good morning, everyone. Hi. I'm Liz Barrett, and I'm the CEO of UroGen Pharma. Thank you for joining us today. We're here in Washington, D.C. at the AUA. Very excited to be here, a very exciting time for our company. I'm going to talk to you a little bit through the agenda today, and then we have an exciting agenda for you, and then there'll be an opportunity for Q&A at the end.

So of course, our normal disclaimers here. I won't read them. Thank goodness. We won't have time for that. We wouldn't have time for anything else. The agenda, I'm exciting after I'm going to make a few opening remarks, show you a few slides. I'm going to turn it over to Dr. Schoenberg and he's going to moderate a panel discussion with our esteemed urologists. You'll be excited to hear from them. All of them have had experience with ZUSDURI, and we're very excited about that. But more importantly, actually, I have the opportunity to interview and share with you a story of a patient who has received ZUSDURI and recently received a complete response. So I'm very excited about that, and I think you'll enjoy it. And then again, as I said, we'll have an opportunity for Q&A.